This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dump These 4 Toxic Stocks or Sell Short for Timely Profits
by Zacks Equity Research
Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.
Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem
by Zacks Equity Research
Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs
by Sweta Jaiswal, FRM
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.
AstraZeneca's Lynparza Gets FDA Nod for New Ovarian Cancer Use
by Zacks Equity Research
FDA approves AstraZeneca's (AZN) PARP inhibitor Lynparza as a first-line maintenance treatment for HRD-positive advanced ovarian cancer. The approval was based on data from the phase III PAOLA-1 study.
Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View
by Zacks Equity Research
Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Safeguard Your Portfolio by Abandoning These 4 Toxic Stocks
by Zacks Equity Research
Dump or short sell these four toxic stocks from your portfolio to avoid losses.
Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement
by Zacks Equity Research
Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.
Myriad Grows Internationally, Hereditary Cancer Revenues Soft
by Zacks Equity Research
Myriad Genetics (MYGN) registers soft Hereditary Cancer, GeneSight, Vectra as well as Prenatal revenues in second-quarter fiscal 2020.
Myriad (MYGN) Down 44.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems
by Zacks Equity Research
Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems
Dump These 5 Toxic Stocks Right Away
by Zacks Equity Research
Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On
by Sriparna Ghosal
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Steer Clear Of These 5 Toxic Stocks Before It's Too Late
by Zacks Equity Research
Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.
Myriad Genetics (MYGN) Releases Favorable Prolaris Results
by Zacks Equity Research
This study result is a major breakthrough and is expected to strengthen Myriad Genetics' (MYGN) Oncology segment.
Myriad Genetics (MYGN) Files for myChoice CDx Test sPMA
by Zacks Equity Research
With the receipt of the regulatory approval, Myriad Genetics (MYGN) will be taking a major stride forward in its Oncology and Women's Health segment.
Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.
Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of -25.81% and -6.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Myriad Genetics (MYGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging
by Zacks Equity Research
The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.
Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.
Myriad Genetics Presents Trial Outcomes in Breast Health
by Zacks Equity Research
Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.
Myriad Genetics Reports Favorable Study Result on Prequel
by Zacks Equity Research
Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.
Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.